Publicaciones en las que colabora con Xavier Montalbán Gairín (34)

2024

  1. Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis

    Journal of Neurology, Neurosurgery and Psychiatry, Vol. 95, Núm. 5, pp. 410-418

2023

  1. XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (I)

    Revista de neurologia, Vol. 77, Núm. 1, pp. 19-30

  2. XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (II)

    Revista de neurologia, Vol. 77, Núm. 2, pp. 47-60

2021

  1. XIII Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2020 (I)

    Revista de neurologia, Vol. 72, Núm. 11, pp. 397-406

  2. XIII Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2020 (II)

    Revista de neurologia, Vol. 72, Núm. 12, pp. 433-442

2016

  1. Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes

    Journal of Neurology, Vol. 263, Núm. 7, pp. 1349-1360

2012

  1. Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II).

    Revista de neurologia, Vol. 54, Núm. 12, pp. 734-749

  2. Revisión de las novedades presentadas en el XXVII Congreso del Comité Europeo para el Tratamiento e Investigación en Esclerosis Múltiple (ECTRIMS) (I)

    Revista de Neurologia, Vol. 54, Núm. 11, pp. 677-691

2011

  1. Interferon beta-1b for the treatment of primary progressive multiple sclerosis: Five-year clinical trial follow-up

    Archives of Neurology, Vol. 68, Núm. 11, pp. 1421-1427

2010

  1. Clinical features of CIS of the brainstem/cerebellum of the kind seen in MS

    Journal of Neurology, Vol. 257, Núm. 5, pp. 742-746

2009

  1. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis

    Brain, Vol. 132, Núm. 9, pp. 2517-2530

  2. Primary progressive multiple sclerosis diagnostic criteria: A reappraisal

    Multiple Sclerosis, Vol. 15, Núm. 12, pp. 1459-1465

  3. Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required

    Multiple Sclerosis, Vol. 15, Núm. 11, pp. 1303-1310

2008

  1. Acute disseminated encephalomyelitis: Study of factors involved in a possible development towards multiple sclerosis

    Neurologia, Vol. 23, Núm. 9, pp. 546-554

  2. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?

    Neurology, Vol. 70, Núm. 13 PART 2, pp. 1079-1083

  3. Induction of serum soluble tumor necrosis factor receptor II (sTNF-RII) and interleukin-1 receptor antagonist (IL-1ra) by interferon beta-1b in patients with progressive multiple sclerosis

    Journal of Neurology, Vol. 255, Núm. 8, pp. 1136-1141

  4. Relationship between MRI lesion activity and response to IFN-β in relapsing-remitting multiple sclerosis patients

    Multiple Sclerosis, Vol. 14, Núm. 4, pp. 479-484

  5. The basal ganglia: A substrate for fatigue in multiple sclerosis

    Neuroradiology, Vol. 50, Núm. 1, pp. 17-23

  6. Very early scans for demonstrating dissemination in time in multiple sclerosis

    Multiple Sclerosis, Vol. 14, Núm. 5, pp. 631-635

2007

  1. Interferon beta in secondary progressive multiple sclerosis: Daily clinical practice

    Journal of Neurology, Vol. 254, Núm. 7, pp. 849-853